| scholarly article | Q13442814 |
| P356 | DOI | 10.1017/S003329170003347X |
| P698 | PubMed publication ID | 7480436 |
| P50 | author | Tadafumi Kato | Q37378746 |
| P2093 | author name string | S Takahashi | |
| Y Takahashi | |||
| T Shioiri | |||
| H Hamakawa | |||
| T Inubushi | |||
| J Murashita | |||
| P2860 | cites work | A rating scale for depression | Q24564540 |
| Measurement of brain phosphoinositide metabolism in bipolar patients using in vivo 31P-MRS | Q28321813 | ||
| "No longer Gage": frontal lobe dysfunction and emotional changes | Q34454862 | ||
| ATP and brain function | Q38597443 | ||
| Affective disorders and cerebral vascular disease | Q38687888 | ||
| Neuroanatomical studies of major affective disorders. A review and suggestions for further research | Q39577028 | ||
| The effects of lateralized frontal lesions on mood regulation | Q41477425 | ||
| Evidence for common alterations in cerebral glucose metabolism in major affective disorders and schizophrenia | Q43599217 | ||
| Brain phosphorous metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy | Q43737909 | ||
| D1 dopamine receptor binding in mood disorders measured by positron emission tomography | Q43784235 | ||
| Abnormal cerebral laterality in bipolar depression: convergence of behavioral and brain event-related potential findings | Q43853071 | ||
| Regional cerebral blood flow in patients with affective disorders | Q44289118 | ||
| Reduction of prefrontal cortex glucose metabolism common to three types of depression | Q45097380 | ||
| Reduction of brain phosphocreatine in bipolar II disorder detected by phosphorus-31 magnetic resonance spectroscopy | Q48111389 | ||
| Comparison of mania and depression after brain injury: causal factors | Q48116783 | ||
| 11C-glucose metabolism in manic and depressed patients | Q48213368 | ||
| The possible association between affective disorder and partially deleted mitochondrial DNA. | Q48345913 | ||
| Alterations in brain phosphorous metabolism in bipolar disorder detected by in vivo 31P and 7Li magnetic resonance spectroscopy | Q48360326 | ||
| Frontal cortex and basal ganglia metabolic rates assessed by positron emission tomography with [18F]2-deoxyglucose in affective illness | Q48374304 | ||
| SPECT findings in patients with primary mania | Q48377537 | ||
| Cerebral metabolic rates for glucose in mood disorders. Studies with positron emission tomography and fluorodeoxyglucose F 18. | Q48493217 | ||
| Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls | Q48712843 | ||
| Determination of side of cerebral dominance with amobarbital. | Q51303996 | ||
| A new scale for the longitudinal rating of manic states. | Q51315032 | ||
| CSF magnesium in affective disorder: lack of correlation with clinical course of treatment. | Q52028944 | ||
| Insulin tolerance test: human growth hormone response and insulin resistance in primary unipolar depressed, bipolar depressed and control subjects. | Q52099409 | ||
| Creatinine and creatine in CSF: indices of brain energy metabolism in depression. Short note | Q67934191 | ||
| The trouble with spectroscopy papers | Q68020321 | ||
| Regional cerebral blood flow in depression and mania | Q69367821 | ||
| P433 | issue | 3 | |
| P921 | main subject | bipolar disorder | Q131755 |
| P304 | page(s) | 557-566 | |
| P577 | publication date | 1995-05-01 | |
| P1433 | published in | Psychological Medicine | Q7256364 |
| P1476 | title | Lateralized abnormality of high energy phosphate metabolism in the frontal lobes of patients with bipolar disorder detected by phase-encoded 31P-MRS | |
| P478 | volume | 25 |
| Q48864019 | 31P Nuclear magnetic resonance spectroscopy findings in bipolar illness: a meta-analysis |
| Q36829054 | 31P magnetic resonance spectroscopy studies in schizophrenia |
| Q47695444 | A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression |
| Q36119909 | A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders--focus on magnetic resonance spectroscopy (MRS) studies |
| Q35204087 | Affective disorders, antidepressant drugs and brain metabolism |
| Q40837419 | Altered intrinsic functional connectivity in language-related brain regions in association with verbal memory performance in euthymic bipolar patients |
| Q37143399 | Bipolar disorder: from genes to behavior pathways |
| Q48550999 | Brain electrical tomography in depression: the importance of symptom severity, anxiety, and melancholic features. |
| Q34692741 | Cell pathology in bipolar disorder |
| Q28251880 | Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder |
| Q92268464 | Cerebral bioenergetic differences measured by phosphorus-31 magnetic resonance spectroscopy between bipolar disorder and healthy subjects living in two different regions suggesting possible effects of altitude |
| Q44204395 | Chronic treatment with both lithium and sodium valproate may normalize phosphoinositol cycle activity in bipolar patients |
| Q33866397 | Decreased brain PME/PDE ratio in bipolar disorder: a preliminary (31) P magnetic resonance spectroscopy study. |
| Q36728449 | Energetic and cell membrane metabolic products in patients with primary insomnia: a 31-phosphorus magnetic resonance spectroscopy study at 4 tesla |
| Q50852072 | Failure to demonstrate parent-of-origin effect in transmission of bipolar II disorder. |
| Q36295874 | Frontal lobe bioenergetic metabolism in depressed adolescents with bipolar disorder: a phosphorus-31 magnetic resonance spectroscopy study |
| Q48599205 | Increased levels of a mitochondrial DNA deletion in the brain of patients with bipolar disorder |
| Q40722575 | Mitochondrial DNA polymorphisms in bipolar disorder |
| Q34137363 | Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia |
| Q31088436 | Mitochondrial dysfunction as the molecular basis of bipolar disorder: therapeutic implications. |
| Q30640247 | Mitochondrial dysfunction in bipolar disorder |
| Q30995022 | Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research |
| Q30985980 | Mitochondrial dysfunction in bipolar disorder: from 31P-magnetic resonance spectroscopic findings to their molecular mechanisms. |
| Q22241837 | Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development |
| Q37072337 | Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. |
| Q48883763 | Mood stabilizer lithium inhibits amphetamine-increased 4-hydroxynonenal-protein adducts in rat frontal cortex |
| Q48498017 | Multiple regression analysis of relationship between frontal lobe phosphorus metabolism and clinical symptoms in patients with schizophrenia |
| Q37060166 | Neurochemical abnormalities in unmedicated bipolar depression and mania: a 2D 1H MRS investigation |
| Q30640237 | Neuroimaging in bipolar disorder |
| Q34111006 | Neuroplasticity and cellular resilience in mood disorders |
| Q34084286 | Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness. |
| Q48303064 | P300 topography differs in schizophrenia and manic psychosis |
| Q40900359 | Platelet membrane phosphatidylinositol-4,5-bisphosphate alterations in bipolar disorder--evidence from a single case study |
| Q34674792 | Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics |
| Q57405124 | Quantitative analysis of leukocyte mitochondrial DNA deletion in affective disorders |
| Q43593933 | Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder |
| Q48550977 | Regional prefrontal gray and white matter abnormalities in bipolar disorder |
| Q34268156 | Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorder |
| Q41628317 | The functional neuroanatomy of mood disorders |
| Q35135220 | Unchanged packing density but altered size of neurofilament immunoreactive neurons in the prefrontal cortex in schizophrenia and major depression. |
| Q97549114 | Valproate inhibits mitochondrial bioenergetics and increases glycolysis in Saccharomyces cerevisiae |
Search more.